Clinical Scorecard: Vamikibart Shows Early Safety in Uveitic Macular Edema

At a Glance

Key Highlights

• No sustained intraocular pressure elevations or new cataracts reported with vamikibart.
• Over 80% of participants had complete resolution of intraretinal fluid by week 12.
• Improvements in visual acuity maintained through 36 weeks in lower dose groups.
• No drug-related serious adverse events reported in the DOVETAIL trial.
• Current therapies like corticosteroids have significant limitations.

Guideline-Based Recommendations

Diagnosis

• Assess uveitic macular edema through clinical examination and imaging.

Management

• Consider corticosteroids as standard treatment, but evaluate for potential adverse effects.

Monitoring & Follow-up

• Monitor intraocular pressure and visual acuity regularly.

Risks

• Corticosteroids are associated with cataract formation and elevated intraocular pressure.

Patient & Prescribing Data

Patients with anterior, intermediate, posterior, and panuveitis.

Vamikibart shows promise in safety and tolerability, but efficacy remains to be established.

Clinical Best Practices

• Conduct thorough patient assessments prior to initiating treatment.
• Monitor for intraocular inflammation and visual outcomes during follow-up.
• Consider participation in ongoing clinical trials for access to novel therapies.

Related Resources & Content

• JAMA Ophthalmology